ArticleEuropean journal of nuclear medicine and molecular imaging2026
Tumor absorbed dose and outcomes after Y-90 glass radioembolization for colorectal liver metastases: does dose escalation improve survival in real-world practice?
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the dose-response and dose-survival outcomes of yttrium-90 (Y90) transarterial radioembolization (TARE) using Therasphere microspheres in patients with colorectal cancer liver metastases (CRCLM). MATERIAL AND
methodsBetween May 2014 and December 2024, patients with chemorefractory CRCLM who underwent Y90 TARE using glass microspheres were retrospectively included. Patients were divided into two groups according to tumour absorbed dose (TAD): TAD<189 Gy (group 1) and TAD ≥189 Gy (group 2). The primary outcomes were overall survival (OS) and hepatic progression-free survival (hPFS). The secondary outcome was the objective response rate (ORR).
resultsA total of seventy-eight patients with a mean age of 69.9±11.2 years (range 41 to 91 years) were included. The median tumor dose and the median OS were 171.5 Gy (IQR; 147-200 Gy) and 8.9 months ( IQR; 5-14 months), respectively. The median TAD for groups 1 (n=46) and 2 (n=32) was 150 Gy (IQR; 122-166 Gy) and 202 Gy (IQR; 195-232 Gy), respectively. The median OS and hPFS for group 1 versus group 2 were 9.4 months (IQR; 6.7-17.7 months) and 5.2 months (IQR; 4-6.7 months) versus 7.1 months (IQR; 5-10.7 months) and 5.5 months (IQR; 4.2-6.7 months), respectively and were not significantly different (p = .107 and p = .663, respectively). The ORR did not differ significantly between the two groups (p = .943).
conclusionIn a real-world population of heavily pretreated patients with CRCLM, escalation of TAD beyond 189 Gy did not translate into improved survival, highlighting the dominant impact of advanced disease burden and extrahepatic progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.